The Move to Bundled Payments Will Be Paradigm-Changing

Article

As with any legislation, there are both positive and negative aspects. Specific to oncology, one of the greatest impacts of the ACA will be the move to a bundled payment for a treatment of a disease.

Bruce Minsky, MD

It is difficult to comment on the full impact of the Affordable Care Act (ACA), since it is complex and how each provision will impact each component of health care is still not fully understood. As with any legislation, there are both positive and negative aspects.

Specific to oncology, one of the greatest impacts of the ACA will be the move to a bundled payment for a treatment of a disease. This will refocus the question in multidisciplinary tumor boards from “what is the ideal way to stage, treat, and manage the patient” to “what is the ideal way to stage, treat, and manage the patient within the reimbursement envelope for their disease.”  The ultimate impact of these 7 paradigm-changing words remains to be determined.

More on the Supreme Court Decision

Derek Raghavan
Bruce Minsky
Nora Janjan
Michael Glod
James B. Yu
Lawrence Wagman
Recent Videos
Yale’s COPPER Center aims to address disparities and out-of-pocket costs for patients, thereby improving the delivery of complex cancer treatment.
7 experts are featured in this series.
7 experts are featured in this series.
A study presented at ASTRO 2025 evaluated the feasibility of using a unified cancer database to consolidate information gathered across 14 institutions.
Non-Hodgkin lymphoma and other indolent forms of disease may require sequencing new treatments for years or decades, said Scott Huntington, MD, MPH, MSc.
Fixed-duration therapy may be more suitable for younger patients, while continuous therapy may benefit those who are older with more comorbidities.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ESMO Annual Congress, from hot topics and emerging trends to travel recommendations.
Andrezj Jakubowiak, MD, PhD, prioritizes KRd-based regimens for the treatment of high-risk newly diagnosed disease in the post-transplant setting.
2 KOLs are featured in this series.
Related Content